NASDAQ$AHCO

AdaptHealth Corp. · Q4 2020 earnings

Q4 2020 earnings · · Investor relations

Briefing

AdaptHealth reported strong Q4 2020 financial results, driven by growth in the diabetes business and accretive acquisitions.

AdaptHealth Corp. announced financial results for the fourth quarter and full year ended December 31, 2020. The company is increasing its previously issued financial guidance for fiscal year 2021.

  • Diabetes business drove substantial growth due to high ordering patterns in December.
  • Continued investment in accretive acquisitions contributed to growth.
  • Increased guidance for 2021 due to acquisitions and organic growth prospects.
  • Integration of AdaptHealth and AeroCare is progressing smoothly, with a focus on achieving cost synergies and enhancing organic growth.

Headline financials

Total Revenue

$348M

Previous: $150M+133.0%
EPS (adj)

-$0.47

Previous: $0.13-461.5%
Adjusted EBITDA

$82.3M

No prior period
Capital Expenditures

$16.9M

Previous: $6.88M+146.0%
Free Cash Flow

$33.4M

Previous: $55.3M-39.6%
Net Income

-$21.2M

Previous: -$3.43M-518.8%
Operating Income

$17.4M

Previous: $714K+2337.0%
Gross Profit

$58M

Previous: $26.3M+120.5%
Cash & Equivalents

$190M

Previous: $76.9M+147.7%
Total Assets

$3.77B

Previous: $547M+590.6%
Stock-Based Comp

$7.7M

Previous: $5.26M+46.3%

Revenue & EPS history

AdaptHealth · Revenue · Quarterly

$348M

Q4 2020+133%vs Q4 2019
Beat estimate in 4 of 9 quarters(44%)
ActualEstimate

Forward guidance

The Company is increasing its previously issued financial guidance for fiscal year 2021.

Tailwinds

  • Acquisitions
  • Organic growth in 2021
  • Underlying growth in the diabetes business
  • Investments in chronic disease businesses such as obstructive sleep apnea
  • Enhanced scale of the combined AdaptHealth and AeroCare

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2020

Historical avgQ4 2020

+0.6%

Avg return

Earnings day

+1.4%

Avg return

5 days after

+1.6%

Avg return

30 days after

52%

16 / 31 earnings

Positive

+34.6%

Q4 2023

Best reaction

-27.9%

Q4 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-10.0%-13.4%-25.6%
Q4 2025-14.2%-11.1%+10.9%
Q3 2025+17.2%+4.5%+3.2%
Q1 2025+1.7%-1.4%+3.7%
Q4 2024+24.4%+33.1%+24.4%
Q3 2024+0.3%-0.6%-4.2%
Q2 2024-17.2%-14.1%+4.6%
Q1 2024-8.6%-8.8%+4.9%
Q4 2023+34.6%+37.9%+50.9%
Q3 2023-23.1%-18.6%-5.6%
Q2 2023+11.1%+4.4%-19.8%
Q1 2023-8.4%-12.2%-13.8%
Q4 2022-27.9%-27.9%-40.6%
Q3 2022-1.6%+8.4%+4.5%
Q2 2022-8.9%-8.2%-25.7%
Q1 2022+23.7%+42.2%+53.6%
Q4 2021+4.1%+2.3%+2.8%
Q3 2021-5.4%-7.2%-24.1%
Q2 2021+16.4%+13.4%+12.3%
Q1 2021-8.5%-14.9%-10.4%
Q4 2020+2.1%+12.4%+21.7%
Q3 2020+2.6%+0.6%+19.5%
Q2 2020+13.9%+18.0%+7.0%
Q1 2020+1.6%+5.8%+5.5%
Q4 2019+1.8%+1.4%-7.7%
Q3 2019-4.1%-4.9%-3.3%
Q2 2019+0.0%+0.0%-0.6%
Q1 2019+0.0%+0.0%+0.3%
Q4 2018+0.6%+0.7%+1.3%
Q3 2018+0.3%+0.1%+0.4%
Q2 2018+0.0%+0.3%+0.1%
Q1 2018

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro